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Bio-Medical
Antibodies Against Three Forms of Urokinase
These antibodies can be used to measure small quantities of three molecular forms of urokinase.
Lyndon B. Johnson Space Center, Houston, Texas
Antibodies that bind to preselected
regions of the urokinase molecule
have been developed. These antibod-
ies can be used to measure small quan-
tities of each of three molecular forms
of urokinase that could be contained
in microsamples or conditioned
media harvested from cultures of
mammalian cells. Previously available
antibodies and assay techniques do
not yield both clear distinctions
among, and measurements of, all
three forms.
Urokinase is a zymogen that is synthe-
sized in a single-chain form, called
“ScuPA,” which is composed of 411
amino acid residues (see figure). ScuPA
has very little enzyme activity, but it can be
activated in two ways: (1) by cleavage of
the peptide bond lysine 158/isoleucine
159 and the loss of lysine 158 to obtain
the high molecular-weight (HMW) form
of the enzyme or (2) by cleavage of the
bond lysine 135/lysine 136 to obtain the
low-molecular-weight (LMW) form of the
enzyme.
The antibodies in question were pro-
duced in mice and rabbits by use of pep-
tides as immunogens. The peptides were
selected to obtain antibodies that bind
to regions of ScuPA that include the ly-
sine 158/isoleucine 159 and the lysine
135/lysine 136 bonds. The antibodies
include monoclonal and polyclonal
ones that yield indications as to whether
either of these bonds is intact. The poly-
clonal antibodies include ones that
preferentially bind to the HMW or LMW
forms of the urokinase molecule. The
Urokinase is synthesized in this form, called “ScuPA,” containing 411 amino acid residues. The enzyme is activated by cleaving at the bonds indicated by
the arrows. Antibodies can be tailored to distinguish among the active and inactive forms.
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monoclonal antibodies include ones
that discriminate between the ScuPA
and the HMW form. A combination of
these molecular-specific antibodies will
enable simultaneous assays of the ScuPA,
HMW, and LMW forms in the same spec-
imen of culture medium.
This work was done by Dennis R. Morrison
of Johnson Space Center and M. Zouhair
Atassi of Baylor College of Medicine. For fur-
ther information, contact the Johnson Com-
mercial Technology Office at (281) 483-3809.
This invention is owned by NASA, and a
patent application has been filed. Inquiries
concerning nonexclusive or exclusive license
for its commercial development should be ad-
dressed to the Patent Counsel, Johnson Space
Center, (281) 483-0837. Refer to MSC-
21947.
The materials included in the collec-
tion of documents describe the research
of the NASA Ames Fatigue Countermea-
sures Group (FCG), which examines the
extent to which fatigue, sleep loss, and
circadian disruption affect flight-crew
performance. The group was formed in
1980 — in response to a Congressional
request to examine a possible safety
problem of uncertain magnitude due to
transmeridian flying and a potential
problem due to fatigue in association
with various factors found in air-trans-
port operations — and was originally
called the Fatigue/Jet Lag Program.
The goals of the FCG are: (1) the devel-
opment and evaluation of strategies for
mitigating the effects of sleepiness and
circadian disruption on pilot perform-
ance levels; (2) the identification and
evaluation of objective approaches for
the prediction of alertness changes in
flight crews; and (3) the transfer and ap-
plication of research results to the oper-
ational field via classes, workshops, and
safety briefings. 
Some of the countermeasure ap-
proaches that have been identified to be
scientifically valid and operationally rele-
vant are brief naps (<40 min) in the cock-
pit seat and 7-min activity breaks, which
include postural changes and ambula-
tion. Although a video-based alertness
monitor based on slow eyelid closure
shows promise in other operational envi-
ronments, research by the FCG has
demonstrated that in its current form at
the time of this reporting, it is not feasible
to implement it in the cockpit. Efforts also
focus on documenting the impact of un-
treated fatigue on various types of flight
operations. For example, the FCG re-
cently completed a major investigation
into the effects of ultra-long-range flights
(20 continuous hours in duration) on the
alertness and performance of pilots in
order to establish a baseline set of param-
eters against which the effectiveness of
new ultra-long-range fatigue remedies can
be judged. 
This work was done by Melissa Mallis,
David Neri, Mark Rosekind, and Philippa
Gander of Ames Research Center; John Cald-
well of Air Force Research Laboratory; and
Curtis Graeber of The Boeing Company. For
further information, visit the FCG website at
http://human-factors.arc.nasa.gov/zteam.
Inquiries concerning rights for the commer-
cial use of this invention should be addressed
to the Ames Technology Partnerships Division
at (650) 604-2954. Refer to ARC-15114-1.
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